Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

• Published in: Annals of hematology Vol. 98; no. 4; pp. 889 - 896
• Main Authors: Breccia, Massimo, Bartoletti, Daniela, Bonifacio, Massimiliano, Palumbo, Giuseppe A., Polverelli, Nicola, Abruzzese, Elisabetta, Bergamaschi, Micaela, Tieghi, Alessia, Tiribelli, Mario, Iurlo, Alessandra, Cavazzini, Francesco, Sgherza, Nicola, Binotto, Gianni, Isidori, Alessandro, D’Adda, Mariella, Crugnola, Monica, Bosi, Costanza, Heidel, Florian, Molica, Matteo, Scaffidi, Luigi, Cattaneo, Daniele, Latagliata, Roberto, Auteri, Giuseppe, Lemoli, Roberto M., Fanin, Renato, Russo, Domenico, Aversa, Franco, Cuneo, Antonio, Semenzato, Gianpietro, Catani, Lucia, Cavo, Michele, Vianelli, Nicola, Foà, Robin, Palandri, Francesca
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.04.2019; Springer Nature B.V
• Subjects: Anemia; Body mass index; Comorbidity; Hematology; Inhibitor drugs; Medicine; Medicine & Public Health; Oncology; Original Article; Spleen; CCI; Ruxolitinib; Myelofibrosis; Comorbidities; BMI

Comorbidities defined by the Charlson comorbidity index (CCI) and body mass index (BMI) are significantly associated with outcome in patients who receive continuous treatment with tyrosine kinase inhibitors. We evaluated the impact of CCI and BMI on responses, drug-related toxicities, and outcome in...